| Literature DB >> 33887395 |
Shuang Wang1, Juan Li1, Yingjuan He1, Yonghong Ran1, Binghui Lu1, Jining Gao1, Chang Shu1, Jie Li1, Yazhen Zhao1, Xin Zhang2, Yuhui Hao3.
Abstract
Radiation-induced lung injury (RILI) is a complication commonly found in victims suffering from nuclear accidents and patients treated with chest tumor radiotherapy, and drugs are limited for effective prevention and treatment. Melatonin (MET) has an anti-radiation effect, but its metabolic period in the body is short. In order to prolong the metabolism period of MET, we prepared MET entrapped poly (lactic-co-glycolic acid) nanoparticles (MET/PLGANPS) for the treatment of RILI. As a result, the release rate of MET/PLGANPS in vitro was lower than MET, with stable physical properties, and it caused no changes in histopathology and biochemical indicators. After 2 weeks and 16 weeks of irradiation with the dose of 15 Gy, MET and MET/PLGANPS could reduce the expression of caspase-3 proteins, inflammatory factors, TGF-β1 and Smad3 to alleviate radiation-induced lung injury. MET/PLGANPS showed better therapeutic effect on RILI than MET. In addition, we also found that high expression of miR-21 could increase the expression levels of TGF-β1, and inhibit the protective effect of MET/PLGANPS. In conclusion, MET/PLGANPS may alleviate RILI by inhibiting the miR-21/TGF-β1/Smad3 pathway, which would provide a new target for the treatment of radiation-induced lung injury.Entities:
Keywords: Melatonin; Nanoparticles; Radiation-induced lung injury; Smad3; TGF-β1; miR-21
Year: 2021 PMID: 33887395 DOI: 10.1016/j.ijpharm.2021.120584
Source DB: PubMed Journal: Int J Pharm ISSN: 0378-5173 Impact factor: 5.875